Citation Impact
Citing Papers
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
2007
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
2009 Standout
Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register
2008
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
2017
From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.
2014 Standout
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
2009 Standout
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial
2010
Psoriasis
2014
Guidelines of care for the management of psoriasis and psoriatic arthritis
2008
Atopic Dermatitis
2008 Standout
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
2015
Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
2007
IL-31: A new link between T cells and pruritus in atopic skin inflammation
2006 Standout
Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis
2012 Standout
Psoriasis
2009 Standout
The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results
2008 Standout
Cost‐effectiveness of psoriasis therapy with etanercept in Germany
2007
Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study
2008
Atopic dermatitis
2003 Standout
Calcineurin Inhibitor Nephrotoxicity
2009 Standout
Treatment of Sjögren's syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study
2015
CCR6 is required for IL-23–induced psoriasis-like inflammation in mice
2009
Hidradenitis suppurativa: A comprehensive review
2009 Standout
Efficacy of systemic therapies for moderate‐to‐severe psoriasis: a systematic review and meta‐analysis of long‐term treatment
2012
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
2015
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
2022 StandoutNobel
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
2008 Standout
Pathogenesis and therapy of psoriasis
2007 StandoutNature
Atopic dermatitis
2015 Standout
Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials
2005
Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial
2005
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
2017
Psoriasis
2021 Standout
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
2014 Standout
The retinoid X receptors and their ligands
2011
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study
2008
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
2012
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
2013
Microbial colonization and atopic dermatitis
2004
Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis
2006
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
2017
Efficacy of etanercept in an integrated multistudy database of patients with psoriasis
2006
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years
2012
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Psoriasis
2015 Standout
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Erythrodermic psoriasis: pathophysiology and current treatment perspectives
2016
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Type 2 diabetes and psoriasis: links and risks
2019
TNFα blockade in human diseases: An overview of efficacy and safety
2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
2015
TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis
2011
The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation
2008 Standout
TFOS DEWS II Management and Therapy Report
2017 Standout
Immunopathogenesis of Psoriasis
2007
Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis
2006
A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis
2016
Guidelines of care for the management of psoriasis and psoriatic arthritis
2008
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis
2006
Clinical Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops
2012
Cancer-related fatigue—mechanisms, risk factors, and treatments
2014 Standout
Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics
2007
The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder
2006
CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials
2011 Standout
Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges
2020
Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction
2011
From inflammation to sickness and depression: when the immune system subjugates the brain
2007 Standout
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial
2005
Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
2008
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
2007
Anti-cytokine therapies for psoriasis
2011
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
2018
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
2018 Standout
Allergic contact dermatitis in dental professionals
2003
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
2014 Standout
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
2013
The role of inflammation in depression: from evolutionary imperative to modern treatment target
2015 Standout
The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
2013
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis
2016
Infliximab for the treatment of adults with psoriasis
2009
Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery
2013 Standout
Antidrug antibodies in psoriasis: a systematic review
2013
Once-Weekly Administration of High-Dosage Etanercept in Patients with Plaque Psoriasis: Results of a Pilot Experience (Power Study)
2006
Psoriasis Pathogenesis and Treatment
2019 Standout
‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
2014
Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial
2015
Immunology of Psoriasis
2014 Standout
IL-17 and Th17 Cells
2009 Standout
Atopic dermatitis: A practice parameter update 2012
2013
Guidelines for Infection Control in Dental Health Care Settings
2013 Standout
The effectiveness and cost-effectiveness of pimecrolimus and tacrolimus for atopic eczema: a systematic review and economic evaluation
2005
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Thyroid Hormone Regulation of Metabolism
2014 Standout
A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
2016
Infliximab for the treatment of plaque psoriasis
2008
The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction
2011 Standout
Alitretinoin for the treatment of severe chronic hand eczema
2010
Psoriasis
2011
Treatment of Childhood Atopic Dermatitis and Economic Burden of Illness in Asia Pacific Countries
2015 Standout
The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials
2013
TNF‐mediated inflammatory disease
2007 Standout
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
2013
CAR T cell immunotherapy for human cancer
2018 StandoutScience
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease
2011 Standout
Consensus Guidelines for the Management of Plaque Psoriasis
2012
Macrolactam Immunomodulators (Tacrolimus and Pimecrolimus): New Horizons in the Topical Treatment of Inflammatory Skin Diseases
2004
Efalizumab for the Treatment of Psoriatic Arthritis
2007
Works of M. Lahfa being referenced
A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity
2006
Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension
2008
Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis
2002
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial
2005
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
2005
Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France
2012
Long‐term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis
2004
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
2008
Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies
2014
Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis
2014
Childhood-onset psoriasis: association with future cardiovascular and metabolic comorbidities
2013